Interested in sharing the research? You can order print copies of many research publications.

Order Reprints

Newsletter Sign-Up

Keep up to date with NPC news and events by signing up for our e-newsletter E.V.I.dently, and our CER Daily Newsfeed.

Subscribe POLICY

Blue Pill or Red Pill: The Limits of Comparative Effectiveness Research

Comparative effectiveness research (CER) has been heralded as a way to reduce health-care costs by determining which treatments provide the most benefit for the largest number of patients. This report warns that by choosing "winners and losers," CER drug trials may leave patients who best respond to the "losing" drug without coverage.

The report, conducted by researchers Tomas Philipson and Eric Sun of the Manhattan Institute's Project FDA, examines a CER trial for antipsychotic drugs in the Medicaid program and finds that applying restrictive reimbursement for "losing" drugs could actually reduce patient health and increase health-care costs. By limiting coverage for more expensive drugs that benefit patients outside the average, the authors find that worsened patient health would increase health-care costs by $1.3 billion, outweighing the Medicaid savings.

Dr. Philipson authored a related paper on this topic, "The Impact of Comparative Effectiveness Research on Health and Health Care Spending," that was published in the Journal of Health Economics website.

Blog Post

CER Tweets of the Week: NPC Survey on Medicaid Directors’ CER Views; EU/USA CER Expectations; #HIMSS15 (April 13-17)

This week, comparative effectiveness research (CER) stakeholders welcomed data from the National Pharmaceutical Council’s (@npcnow) survey assessing...
Blog Post

CER Tweets of the Week: NPC and PCORI at AMCP 27th Annual Meeting & Expo (April 6-10)

This week, comparative effectiveness research (CER) stakeholders tweeted from the Academy of Managed Care Pharmacy’s 27th Annual Meeting and Expo (#...
Press Release

State Medicaid Directors Share Views on Comparative Effectiveness Research And Its Impact on Policy in National Pharmaceutical Council Survey

(Washington, DC, April 16, 2015)—A new survey conducted on behalf of the National Pharmaceutical Council (NPC) shows that state Medicaid directors...
Blog Post

#TBT: National Minority Health Month & Health Equity

As part of our “Throwback Thursday” blog series, we’re taking a look at a topic that’s currently in the news and tagging it with previous...
Press Release

State Medicaid Directors Share Views on Comparative Effectiveness Research And Its Impact on Policy in National Pharmaceutical Council Survey

(Washington, DC, April 16, 2015)—A new survey conducted on behalf of the National Pharmaceutical Council (NPC) shows that state Medicaid directors...
Press Release

NPC Highlights Stakeholder Views on Comparative Effectiveness Research and the Environment for Health Care Decision-Making

(Washington, DC, March 26, 2015)—A new survey of health care stakeholders reveals continued optimism that comparative effectiveness research (CER)...
Press Release

Michael Ciarametaro Joins National Pharmaceutical Council as Director of Research

Washington, DC (July 31, 2014)—The National Pharmaceutical Council (NPC) today announced that Michael Ciarametaro has joined the health policy...
Press Release

NPC Study Outlines When & How Health Decision-Makers Should Consider Individual Patient Differences

Washington, DC (July 29, 2014)—New research led by the National Pharmaceutical Council (NPC) can assist health care stakeholders to understand when...
Commentary and Testimony Page

Chain Drug Review – Commentary: “Health Care Outlook for 2015”

This commentary was originally published in the January 5, 2015 issue of Chain Drug Review.By: Dan Leonard, President, National Pharmaceutical...
Commentary and Testimony Page

NPC Comments on PCORI Proposal for Peer Review of Primary Research and Public Release of Research Findings

November 7, 2014Dr. Joe SelbyExecutive DirectorPatient-Centered Outcomes Research Institute1828 L St., NW, Suite 900Washington, DC 20036Dear Dr....
Commentary and Testimony Page

NPC Comments on CMS' Proposed Changes to Protected Classes

March 7, 2014Marilyn B. TavennerAdministratorCenters for Medicare & Medicaid ServicesU.S. Department of Health and Human Services200 Independence...
Commentary and Testimony Page

The State of CER and the Environment for Health Care Decision Making

This month, NPC released its third annual survey on stakeholders’ views on comparative effectiveness research (CER), “The State of Comparative...
YouTube Videos

Comparative Effectiveness Research and the Environment for Health Care Decision-Making

During a March 26, 2015 webinar, the National Pharmaceutical Council discussed the results of its annual stakeholder survey on comparative...
YouTube Videos

Why are quality measures important? We asked health care thought leaders to tell us why.

Quality measurement, tied to financial incentives, is one of many approaches accountable care programs are using to promote system-wide improvement....
YouTube Videos

Real-World Impact of Comparative Effectiveness Research Findings on Clinical Practice

National Pharmaceutical Council Chief Science Officer Robert W. Dubois, MD, PhD, discusses a peer-reviewed study suggesting that changes are needed...
YouTube Videos

Shifting the Focus From "How Much" to "How Well" We Spend Our Health Care Dollars

A. Mark Fendrick, MD, director of the Center for Value-Based Insurance design at the University of Michigan, highlights the key findings from a...
Blog Post

CER Tweets of the Week: NPC Survey on Medicaid Directors’ CER Views; EU/USA CER Expectations; #HIMSS15 (April 13-17)

This week, comparative effectiveness research (CER) stakeholders welcomed data from the National Pharmaceutical Council’s (@npcnow) survey assessing...
Blog Post

CER Tweets of the Week: NPC and PCORI at AMCP 27th Annual Meeting & Expo (April 6-10)

This week, comparative effectiveness research (CER) stakeholders tweeted from the Academy of Managed Care Pharmacy’s 27th Annual Meeting and Expo (#...
Blog Post

#TBT: National Minority Health Month & Health Equity

As part of our “Throwback Thursday” blog series, we’re taking a look at a topic that’s currently in the news and tagging it with previous...
Blog Post

CER Tweets of the Week: NPC in JCER, PCORI Multiple Sclerosis Workshop (March 30 – April 3)

This week, comparative effectiveness research (CER) stakeholders on Twitter shared the Journal of Comparative Effectiveness Research’s (@fsgcer)...
cersurvey-15

2015 Comparative Effectiveness Research and the Environment for Health Care Decision-Making

NPC's fifth annual survey, "Comparative Effectiveness Research (CER) and the Environment for Health...

Exploration of Heterogeneity in Distributed Research Network Drug Safety Analyses

Distributed data network drug safety analyses are di

  •  
  • 1 of 54
  • >